Key Laboratory of Metabolism and Regulation for Major Diseases of Anhui Higher Education Institutes, School of Food and Biological Engineering, Hefei University of Technology, Hefei, 230009, China.
The Institute of Translational Medicine, the National Engineering Research Center for Bioengineering Drugs and the Technologies, Nanchang University, Nanchang, 330031, China.
Acta Pharmacol Sin. 2023 Aug;44(8):1625-1636. doi: 10.1038/s41401-023-01077-8. Epub 2023 Mar 30.
Vascular calcification is caused by the deposition of calcium salts in the intimal or tunica media layer of the aorta, which increases the risk of cardiovascular events and all-cause mortality. However, the mechanisms underlying vascular calcification are not fully clarified. Recently it has been shown that transcription factor 21 (TCF21) is highly expressed in human and mouse atherosclerotic plaques. In this study we investigated the role of TCF21 in vascular calcification and the underlying mechanisms. In carotid artery atherosclerotic plaques collected from 6 patients, we found that TCF21 expression was upregulated in calcific areas. We further demonstrated TCF21 expression was increased in an in vitro vascular smooth muscle cell (VSMC) osteogenesis model. TCF21 overexpression promoted osteogenic differentiation of VSMC, whereas TCF21 knockdown in VSMC attenuated the calcification. Similar results were observed in ex vivo mouse thoracic aorta rings. Previous reports showed that TCF21 bound to myocardin (MYOCD) to inhibit the transcriptional activity of serum response factor (SRF)-MYOCD complex. We found that SRF overexpression significantly attenuated TCF21-induced VSMC and aortic ring calcification. Overexpression of SRF, but not MYOCD, reversed TCF21-inhibited expression of contractile genes SMA and SM22. More importantly, under high inorganic phosphate (3 mM) condition, SRF overexpression reduced TCF21-induced expression of calcification-related genes (BMP2 and RUNX2) as well as vascular calcification. Moreover, TCF21 overexpression enhanced IL-6 expression and downstream STAT3 activation to facilitate vascular calcification. Both LPS and STAT3 could induce TCF21 expression, suggesting that the inflammation and TCF21 might form a positive feedback loop to amplify the activation of IL-6/STAT3 signaling pathway. On the other hand, TCF21 induced production of inflammatory cytokines IL-1β and IL-6 in endothelial cells (ECs) to promote VSMC osteogenesis. In EC-specific TCF21 knockout (TCF21) mice, VD and nicotine-induced vascular calcification was significantly reduced. Our results suggest that TCF21 aggravates vascular calcification by activating IL-6/STAT3 signaling and interplay between VSMC and EC, which provides new insights into the pathogenesis of vascular calcification. TCF21 enhances vascular calcification by activating the IL-6-STAT3 signaling pathway. TCF21 inhibition may be a new potential therapeutic strategy for the prevention and treatment of vascular calcification.
血管钙化是由于主动脉内膜或中膜层的钙盐沉积引起的,这增加了心血管事件和全因死亡率的风险。然而,血管钙化的机制尚未完全阐明。最近的研究表明,转录因子 21(TCF21)在人类和小鼠动脉粥样硬化斑块中高度表达。在这项研究中,我们研究了 TCF21 在血管钙化中的作用及其潜在机制。在从 6 名患者中收集的颈动脉粥样硬化斑块中,我们发现 TCF21 的表达在钙化区域上调。我们进一步证明,在体外血管平滑肌细胞(VSMC)成骨发生模型中,TCF21 的表达增加。TCF21 的过表达促进了 VSMC 的成骨分化,而 VSMC 中的 TCF21 敲低则减弱了钙化。在体外小鼠胸主动脉环中也观察到了类似的结果。先前的报告表明,TCF21 与心肌营养素(MYOCD)结合,抑制血清反应因子(SRF)-MYOCD 复合物的转录活性。我们发现,SRF 的过表达显著减轻了 TCF21 诱导的 VSMC 和主动脉环钙化。SRF 的过表达,而不是 MYOCD 的过表达,逆转了 TCF21 抑制的收缩基因 SMA 和 SM22 的表达。更重要的是,在高无机磷(3mM)条件下,SRF 的过表达降低了 TCF21 诱导的钙化相关基因(BMP2 和 RUNX2)以及血管钙化的表达。此外,TCF21 的过表达增强了白细胞介素 6(IL-6)的表达和下游 STAT3 的激活,以促进血管钙化。LPS 和 STAT3 都可以诱导 TCF21 的表达,表明炎症和 TCF21 可能形成正反馈回路,放大 IL-6/STAT3 信号通路的激活。另一方面,TCF21 在血管内皮细胞(ECs)中诱导产生炎性细胞因子白细胞介素 1β(IL-1β)和白细胞介素 6(IL-6),以促进 VSMC 成骨。在 EC 特异性 TCF21 敲除(TCF21)小鼠中,VD 和尼古丁诱导的血管钙化明显减少。我们的结果表明,TCF21 通过激活 IL-6/STAT3 信号通路以及 VSMC 和 EC 之间的相互作用,加剧血管钙化,为血管钙化的发病机制提供了新的见解。TCF21 通过激活白细胞介素 6-STAT3 信号通路增强血管钙化。TCF21 抑制可能是预防和治疗血管钙化的一种新的潜在治疗策略。
Arterioscler Thromb Vasc Biol. 2014-2-27
Cell Commun Signal. 2024-10-11
J Am Heart Assoc. 2023-1-3
Front Cell Dev Biol. 2025-6-18
Front Endocrinol (Lausanne). 2025-4-2
Cell Commun Signal. 2024-10-11
Front Cardiovasc Med. 2024-5-13
J Am Heart Assoc. 2023-1-3
J Enzyme Inhib Med Chem. 2022-12
Front Cardiovasc Med. 2022-7-19
Curr Atheroscler Rep. 2020-8-9
Br J Pharmacol. 2020-8